Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04829539
Recruitment Status : Recruiting
First Posted : April 2, 2021
Last Update Posted : April 2, 2021
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Stanford University
Information provided by (Responsible Party):
Karen Mustian, University of Rochester NCORP Research Base

Brief Summary:
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-III cancer who are receiving chemotherapy. Chemotherapy can cause side effects such as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Insomnia can be described as difficulty falling asleep, waking up many times during the night or waking up earlier than patient would like. Insomnia can increase fatigue and worsen quality of life. This trial may help researchers determine which treatment works better in reducing insomnia, BBT-CI or HEAL.

Condition or disease Intervention/treatment Phase
Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Behavioral: Behavioral Intervention Other: Quality-of-Life Assessment Other: Questionnaire Administration Not Applicable

Detailed Description:

PRIMARY OBJECTIVE:

I. Determine the efficacy of BBT-CI compared to HEAL as measured by the patient report outcome (PRO) of insomnia (i.e., the Insomnia Severity Index) at post-intervention.

SECONDARY OBJECTIVE:

I. Determine the efficacy of BBT-CI compared to HEAL on sleep efficiency as measured via actigraphy at post intervention.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I (BBT-CI): Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.

GROUP II (HEAL): Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.

After completion of study, patients are followed for up to 6 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
Actual Study Start Date : March 2, 2021
Estimated Primary Completion Date : January 30, 2027
Estimated Study Completion Date : June 30, 2027

Arm Intervention/treatment
Experimental: Group I (BBT-CI)
Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.
Behavioral: Behavioral Intervention
Receive BBT-CI
Other Names:
  • Behavior Conditioning Therapy
  • Behavior Modification
  • Behavior or Life Style Modifications
  • Behavior Therapy
  • Behavioral Interventions
  • Behavioral Modification
  • Behavioral Therapy
  • Behavioral Treatment
  • Behavioral Treatments

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies

Active Comparator: Group II (HEAL)
Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.
Behavioral: Behavioral Intervention
Receive HEAL
Other Names:
  • Behavior Conditioning Therapy
  • Behavior Modification
  • Behavior or Life Style Modifications
  • Behavior Therapy
  • Behavioral Interventions
  • Behavioral Modification
  • Behavioral Therapy
  • Behavioral Treatment
  • Behavioral Treatments

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies




Primary Outcome Measures :
  1. Mean change in the Insomnia Severity Index (ISI) total score [ Time Frame: Baseline to day 42 ]
    The Insomnia Severity Index (ISI) is a validated self-report measure of insomnia. A 5-point Likert Scale of seven questions is used to rate each item (0=no problem; 4=very severe problem), yielding a total score ranging from 0-28 with higher scores indicating higher severity of insomnia. A linear mixed effects analysis of covariance model (ANCOVA) will be used to assess the statistical significance of the differences in mean change between BBT-CI and HEAL.


Secondary Outcome Measures :
  1. Mean change in Sleep Efficiency assessed via Actigraphy [ Time Frame: Baseline to day 42 ]
    Actigraphy will assess sleep efficiency, calculated as the percent of total sleep time to time in bed. Higher percentage indicates better sleep efficiency. A linear mixed effects analysis of covariance model (ANCOVA) will be used to assess the statistical significance of the differences in mean change between BBT-CI and HEAL.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be diagnosed with cancer stage I, II or III
  • Be currently receiving any cytotoxic chemotherapy (can be cytotoxic chemotherapy alone or in combination with biologics and/or antibodies)
  • Report sleep disturbance of 10 or greater (sum total of all 7 items) on the Insomnia Severity Index
  • Have a score of 2, 1, or 0 on the Eastern Cooperative Oncology Group (ECOG) performance status scale
  • Be able to speak, understand and read English to participate in the study assessments and interventions

Exclusion Criteria:

  • Be diagnosed with cancer stage IV
  • Have any type of unstable comorbid medical or psychiatric condition that would prohibit completion of study assessments or intervention per physician or physician's designee
  • Be scheduled to receive active radiation prior to the completion of BBT-CI/HEAL interventions
  • Have a documented or physician's diagnosis of obstructive sleep apnea or restless leg syndrome (even if controlled)
  • Be engaged in a formal Cognitive Behavioral Therapy for Insomnia program presently or in the past 30 days. Use of psychotropics and sleep medication are allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04829539


Contacts
Layout table for location contacts
Contact: Kari Gilliland 585-275-6303 URCC_19185@URMC.Rochester.edu
Contact: Linda Spath 585-275-1364 URCC_19185@URMC.Rochester.edu

Locations
Layout table for location information
United States, New York
University of Rochester NCORP Research Base Recruiting
Rochester, New York, United States, 14642
Contact: Kari Gilliland    585-275-6303    URCC_19185@URMC.Rochester.edu   
Sponsors and Collaborators
University of Rochester NCORP Research Base
National Cancer Institute (NCI)
Stanford University
Investigators
Layout table for investigator information
Principal Investigator: Oxana Palesh Stanford University
Study Chair: Karen Mustian University of Rochester NCORP Research Base
Layout table for additonal information
Responsible Party: Karen Mustian, Professor, University of Rochester NCORP Research Base
ClinicalTrials.gov Identifier: NCT04829539    
Other Study ID Numbers: URCC19185
NCI-2020-07175 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
URCC19185 ( Other Identifier: University of Rochester NCORP Research Base )
URCC-19185 ( Other Identifier: DCP )
URCC19185 ( Other Identifier: CTEP )
R01CA214647 ( U.S. NIH Grant/Contract )
UG1CA189961 ( U.S. NIH Grant/Contract )
First Posted: April 2, 2021    Key Record Dates
Last Update Posted: April 2, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms